175 related articles for article (PubMed ID: 7690176)
1. [Diagnosis of cancer of the prostate by determining the blood levels of specific prostatic antigen, rectal examination, and transrectal echography].
Isa Kroon WA; Robles JE; de Castro F; Rosell D; Abad JI; Zudaire JJ; Berián JM
Actas Urol Esp; 1993 Jun; 17(6):341-5; discussion 345-6. PubMed ID: 7690176
[TBL] [Abstract][Full Text] [Related]
2. [Predictive value of prostate specific antigen density in the detection of prostate cancer in patients with elevated prostate specific antigen levels and normal digital rectal findings or stage A prostate cancer].
Iwaki H; Kajita Y; Shimizu Y; Yamauchi T
Hinyokika Kiyo; 2001 Mar; 47(3):169-74. PubMed ID: 11329957
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1C carcinoma of the prostate.
Presti JC; Hovey R; Carroll PR; Shinohara K
J Urol; 1996 Nov; 156(5):1685-90. PubMed ID: 8863571
[TBL] [Abstract][Full Text] [Related]
4. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
[TBL] [Abstract][Full Text] [Related]
5. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels.
Cookson MS; Floyd MK; Ball TP; Miller EK; Sarosdy MF
J Urol; 1995 Sep; 154(3):1070-3. PubMed ID: 7543601
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
7. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
8. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
Rahardjo D; Kamil ST; Pakasi LS
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
[TBL] [Abstract][Full Text] [Related]
9. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
[TBL] [Abstract][Full Text] [Related]
10. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.
Cirillo S; Petracchini M; D'Urso L; Dellamonica P; Illing R; Regge D; Muto G
BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic approach to prostate cancer using total prostate specific antigen-based parameters together.
Serdar MA; Oguz O; Olgun A; Seçkin B; Ilgan S; Hasimi A; Salih M; Peker F; Kutluay T
Ann Clin Lab Sci; 2002; 32(1):22-30. PubMed ID: 11848613
[TBL] [Abstract][Full Text] [Related]
12. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
13. The value of percent free prostate specific antigen, prostate specific antigen density of the whole prostate and of the transition zone in Turkish men.
Akduman B; Alkibay T; Tuncel A; Bozkirli I
Can J Urol; 2000 Oct; 7(5):1104-9. PubMed ID: 11114873
[TBL] [Abstract][Full Text] [Related]
14. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population.
Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH
J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612
[TBL] [Abstract][Full Text] [Related]
15. [Incidence of prostatic cancer in symptomatic patients with non-suspicious rectal palpation and PSA levels greater than 10 ng/ml].
Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Bueno Chomón G; Leal Hernández F; Bielsa Carrillo A; García Burgos J
Actas Urol Esp; 1999 Apr; 23(4):316-22. PubMed ID: 10394651
[TBL] [Abstract][Full Text] [Related]
16. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for Diagnosis of Prostate Cancer.
Eur Urol; 1997; 32(2):133-9. PubMed ID: 9286642
[TBL] [Abstract][Full Text] [Related]
17. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
18. [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre].
Khouaja K; Ben Sorba N; Bouslama A; Youssef A; Taher Mosbah A
Prog Urol; 2005 Apr; 15(2):255-9. PubMed ID: 15999603
[TBL] [Abstract][Full Text] [Related]
19. [Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood].
Karazanashvili GG; Managadze LG
Urologiia; 2000; (6):37-41. PubMed ID: 11186321
[TBL] [Abstract][Full Text] [Related]
20. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
